{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ZBIO","limit":50},"count":50,"signals":[{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"coup erroneously awarded incentive-based compensation received by each current or former officer of the Company subject to Section16 of the Securities Exchange Act of 1934, as amended, including each named executive officer, in the event the Company is required to prepare an accounting restatement due to its material noncompliance with any financial reporting requirement under the securities laws. The Clawback Policy ge","filed_date":"2026-03-16","accession":"0001104659-26-028062","full_text":"https://origin.rootz.global/static/filing/0001104659-26-028062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"perience delays in completing, or fail to complete, the development and commercialization of our current product candidates or any future product candidates; | | | | Delays or difficulties in the enrollment and dosing of patients in clinical trials, delay or prevent receipt of necessary regulatory approvals; | | | | Any significant adverse events or undesirable side effects caused by our product cand","filed_date":"2026-03-16","accession":"0001104659-26-027964","full_text":"https://origin.rootz.global/static/filing/0001104659-26-027964.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":63,"context":"| | | Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any; | | | | We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunolog","filed_date":"2026-03-16","accession":"0001104659-26-027964","full_text":"https://origin.rootz.global/static/filing/0001104659-26-027964.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"| | | Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any; | | | | We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunolog","filed_date":"2025-11-12","accession":"0001104659-25-109753","full_text":"https://origin.rootz.global/static/filing/0001104659-25-109753.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"perience delays in completing, or fail to complete, the development and commercialization of our current product candidates or any future product candidates; | | | | Delays or difficulties in the enrollment and dosing of patients in clinical trials, delay or prevent receipt of necessary regulatory approvals; | | | | Any significant adverse events or undesirable side effects caused by our product cand","filed_date":"2025-08-12","accession":"0001558370-25-011147","full_text":"https://origin.rootz.global/static/filing/0001558370-25-011147.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"| | | Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any; | | | | We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunolog","filed_date":"2025-08-12","accession":"0001558370-25-011147","full_text":"https://origin.rootz.global/static/filing/0001558370-25-011147.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"| | | Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any; | | | | We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunolog","filed_date":"2025-05-15","accession":"0001558370-25-007803","full_text":"https://origin.rootz.global/static/filing/0001558370-25-007803.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"coup erroneously awarded incentive-based compensation received by each current or former officer of the Company subject to Section16 of the Securities Exchange Act of 1934, as amended, including each named executive officer, in the event the Company is required to prepare an accounting restatement due to its material noncompliance with any financial reporting requirement under the securities laws. The Clawback Policy ge","filed_date":"2025-04-28","accession":"0001104659-25-039765","full_text":"https://origin.rootz.global/static/filing/0001104659-25-039765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"perience delays in completing, or fail to complete, the development and commercialization of our current product candidates or any future product candidates; | | | | Delays or difficulties in the enrollment and dosing of patients in clinical trials, delay or prevent receipt of necessary regulatory approvals; | | | | Any significant adverse events or undesirable side effects caused by our product cand","filed_date":"2025-03-11","accession":"0001558370-25-002631","full_text":"https://origin.rootz.global/static/filing/0001558370-25-002631.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":59,"context":"| | | Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any; | | | | We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunolog","filed_date":"2025-03-11","accession":"0001558370-25-002631","full_text":"https://origin.rootz.global/static/filing/0001558370-25-002631.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"als;  Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any;  We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunological in","filed_date":"2024-11-12","accession":"0001558370-24-015162","full_text":"https://origin.rootz.global/static/filing/0001558370-24-015162.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":34,"context":"ents in the RCP and all patients from the RCP will be eligible for the open-label extension (OLE) period. We expect to conduct the trial at approximately 100 sites in 20 countries and to complete enrollment in 2024. The RCP consists of a screening period (Day -28 to Day-1) and a 52-week treatment period, during which 250 mg of obexelimab or placebo will be administered as an SC injection every seven","filed_date":"2024-09-06","accession":"0001104659-24-097538","full_text":"https://origin.rootz.global/static/filing/0001104659-24-097538.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"als;  Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any;  We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunological in","filed_date":"2024-09-06","accession":"0001104659-24-097538","full_text":"https://origin.rootz.global/static/filing/0001104659-24-097538.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"ly equal installments over the following 36 months, generally subject to Mr. Moulders continued service with us through each vesting date. (11) Represents restricted stock held by Dr. Mu, which was repurchased for $0 on January16, 2024, in accordance with the Restricted Stock Repurchase Agreement by and between Dr.Mu and the Company, dated January1, 2024.  Except for Dr.Mu as described below under Executive Comp","filed_date":"2024-09-06","accession":"0001104659-24-097538","full_text":"https://origin.rootz.global/static/filing/0001104659-24-097538.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"ents in the RCP and all patients from the RCP will be eligible for the open-label extension (OLE) period. We expect to conduct the trial at approximately 100 sites in 20 countries and to complete enrollment in 2024. The RCP consists of a screening period (Day -28 to Day-1) and a 52-week treatment period, during which 250 mg of obexelimab or placebo will be administered as an SC injection every seven","filed_date":"2024-08-22","accession":"0001104659-24-091950","full_text":"https://origin.rootz.global/static/filing/0001104659-24-091950.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"als;  Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any;  We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunological in","filed_date":"2024-08-22","accession":"0001104659-24-091950","full_text":"https://origin.rootz.global/static/filing/0001104659-24-091950.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"to our management. Our board of directors meets on a regular basis and additionally as required.  Upon the consummation of this offering, our board of directors will consist of members, of whom were elected as directors pursuant to the board composition provisions of our Fourth Amended and Restated Shareholders Agreement (the Shareholders Agreement) among us and our stockholders. The Shareholders Agreement will ter","filed_date":"2024-08-22","accession":"0001104659-24-091950","full_text":"https://origin.rootz.global/static/filing/0001104659-24-091950.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"perience delays in completing, or fail to complete, the development and commercialization of our current product candidates or any future product candidates; | | | | Delays or difficulties in the enrollment and dosing of patients in clinical trials, delay or prevent receipt of necessary regulatory approvals; | | | | Any significant adverse events or undesirable side effects caused by our product cand","filed_date":"2025-11-12","accession":"0001104659-25-109753","full_text":"https://origin.rootz.global/static/filing/0001104659-25-109753.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"s or experience delays in completing, or fail to complete, the development and commercialization of our current product candidates or any future product candidates;  Delays or difficulties in the enrollment and dosing of patients in clinical trials delay or prevent receipt of necessary regulatory approvals;  Any significant adverse events or undesirable side effects caused by our product candidates m","filed_date":"2024-11-12","accession":"0001558370-24-015162","full_text":"https://origin.rootz.global/static/filing/0001558370-24-015162.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"perience delays in completing, or fail to complete, the development and commercialization of our current product candidates or any future product candidates; | | | | Delays or difficulties in the enrollment and dosing of patients in clinical trials, delay or prevent receipt of necessary regulatory approvals; | | | | Any significant adverse events or undesirable side effects caused by our product cand","filed_date":"2025-05-15","accession":"0001558370-25-007803","full_text":"https://origin.rootz.global/static/filing/0001558370-25-007803.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":73,"match_count":6,"context":"egal proceedings and claims arising in the ordinary course of business. As of June 30, 2026, the Company was not subject to any material legal proceedings which would reasonably be expected to have a material adverse effect on the Companys financial results. **14.**Related Party Transactions *Xencor, Inc.* The Company has obtained exclusive, worldwide licenses from Xencor to research, develop, manufacture, market and se","filed_date":"2026-08-13","accession":"0001104659-26-095448","full_text":"https://origin.rootz.global/static/filing/0001104659-26-095448.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"25 Financial Results and Provides Corporate Updates** ** ** *- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -* *- Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis; results expected early in the fourth quarter 2025 -* *- Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to","filed_date":"2025-08-12","accession":"0001104659-25-076464","full_text":"https://origin.rootz.global/static/filing/0001104659-25-076464.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"lic offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-* *-Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD)-* *-Advancing multiple obexelimab Phase 2 and Phase 3 clinical trials with results ex","filed_date":"2024-11-12","accession":"0001104659-24-116346","full_text":"https://origin.rootz.global/static/filing/0001104659-24-116346.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":56,"match_count":7,"context":"as broad as intended or desired or obtain approval with significant use or distribution restrictions or safety warnings, be subject to post-marketing testing requirements, or be subject to increased pricing pressure. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also ultimately may lead to the denial of regulatory approval of a product candidate. Further","filed_date":"2026-03-16","accession":"0001104659-26-027964","full_text":"https://origin.rootz.global/static/filing/0001104659-26-027964.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"rate Updates** - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -* *- Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 -* *- Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline","filed_date":"2025-05-15","accession":"0001104659-25-048948","full_text":"https://origin.rootz.global/static/filing/0001104659-25-048948.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"he INDIGO trial, and if successful, the timing of BLA submission, potential approval and commercial launch, the 12 - week and 24 - week topline results from the MoonStone trial, the completion of enrollment and reporting the topline results from the SunStone trial, and if successful, the timing of initiating the Phase 3 trial in SLE, the timing of initiati on of the Phase 3 trial of orelabrutinib in","filed_date":"2025-10-08","accession":"0001104659-25-097663","full_text":"https://origin.rootz.global/static/filing/0001104659-25-097663.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025-* *-Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025-* *- Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025-* *- Out-licensed greater-China anti-IGF-1R Thyroid Eye Disease programs to Zai Lab -* WALTHAM, Mass, F","filed_date":"2025-02-05","accession":"0001104659-25-009368","full_text":"https://origin.rootz.global/static/filing/0001104659-25-009368.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"as broad as intended or desired or obtain approval with significant use or distribution restrictions or safety warnings, be subject to post-marketing testing requirements, or be subject to increased pricing pressure. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also ultimately may lead to the denial of regulatory approval of a product candidate. Further","filed_date":"2025-11-12","accession":"0001104659-25-109753","full_text":"https://origin.rootz.global/static/filing/0001104659-25-109753.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"is expected to initiate in the first quarter of 2026. | | **Other pipeline updates** Obexelimab, a CD19 and FcRIIb inhibitor of B cell function | | | Systemic Lupus Erythematosus (SLE): Continued enrollment in the Phase 2 SunStone trial, a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of obexelimab in patients with SLE. Zenas expects to complete e","filed_date":"2025-11-12","accession":"0001104659-25-109737","full_text":"https://origin.rootz.global/static/filing/0001104659-25-109737.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"as broad as intended or desired or obtain approval with significant use or distribution restrictions or safety warnings, be subject to post-marketing testing requirements, or be subject to increased pricing pressure. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also ultimately may lead to the denial of regulatory approval of a product candidate. Further","filed_date":"2025-08-12","accession":"0001558370-25-011147","full_text":"https://origin.rootz.global/static/filing/0001558370-25-011147.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"as broad as intended or desired or obtain approval with significant use or distribution restrictions or safety warnings, be subject to post-marketing testing requirements, or be subject to increased pricing pressure. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also ultimately may lead to the denial of regulatory approval of a product candidate. Further","filed_date":"2025-05-15","accession":"0001558370-25-007803","full_text":"https://origin.rootz.global/static/filing/0001558370-25-007803.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"as broad as intended or desired or obtain approval with significant use or distribution restrictions or safety warnings, be subject to post-marketing testing requirements, or be subject to increased pricing pressure. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also ultimately may lead to the denial of regulatory approval of a product candidate. Further","filed_date":"2025-03-11","accession":"0001558370-25-002631","full_text":"https://origin.rootz.global/static/filing/0001558370-25-002631.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"s or delays in completing, or failing to complete, the development and commercialization of the Companys current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Companys product candidates; potential competition, including from","filed_date":"2024-12-02","accession":"0001104659-24-124616","full_text":"https://origin.rootz.global/static/filing/0001104659-24-124616.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"as broad as intended or desired or obtain approval with significant use or distribution restrictions or safety warnings, be subject to post-marketing testing requirements, or be subject to increased pricing pressure.Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also ultimately may lead to the denial of regulatory approval of a product candidate. Further,","filed_date":"2024-11-12","accession":"0001558370-24-015162","full_text":"https://origin.rootz.global/static/filing/0001558370-24-015162.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":32,"match_count":4,"context":"e Board of Directors at such meeting, including in accordance with the notice and other provisions of Section 1.2 where applicable, (A) by or at the direction of the Board of Directors or a committee appointed by the Board of Directors and (B) by any stockholders of the Corporation entitled to vote for the election of directors at the meeting exceeds the number of directors to be elected at such meeting, then the election of such","filed_date":"2024-09-16","accession":"0001104659-24-100177","full_text":"https://origin.rootz.global/static/filing/0001104659-24-100177.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"as broad as intended or desired or obtain approval with significant use or distribution restrictions or safety warnings, be subject to post-marketing testing requirements, or be subject to increased pricing pressure.  Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also ultimately may lead to the denial of regulatory approval of a product candidate. Furthe","filed_date":"2024-09-06","accession":"0001104659-24-097538","full_text":"https://origin.rootz.global/static/filing/0001104659-24-097538.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"as broad as intended or desired or obtain approval with significant use or distribution restrictions or safety warnings, be subject to post-marketing testing requirements, or be subject to increased pricing pressure.  Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also ultimately may lead to the denial of regulatory approval of a product candidate. Furthe","filed_date":"2024-08-22","accession":"0001104659-24-091950","full_text":"https://origin.rootz.global/static/filing/0001104659-24-091950.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":29,"match_count":3,"context":"esponsible for overseeing the management of risks relating to accounting matters and financial reporting as well as overall risk management, including with respect to legal and regulatory matters and cybersecurity.  The Compensation Committee is responsible for overseeing the management of risks relating to our executive compensation plans, programs and arrangements.  The Nominating and Corporate Gover","filed_date":"2026-03-16","accession":"0001104659-26-028062","full_text":"https://origin.rootz.global/static/filing/0001104659-26-028062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":29,"match_count":3,"context":"esponsible for overseeing the management of risks relating to accounting matters and financial reporting as well as overall risk management, including with respect to legal and regulatory matters and cybersecurity.  The Compensation Committee is responsible for overseeing the management of risks relating to our executive compensation plans, programs and arrangements.  The Nominating and Corporate Gover","filed_date":"2025-04-28","accession":"0001104659-25-039765","full_text":"https://origin.rootz.global/static/filing/0001104659-25-039765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"ct to a four-year vesting schedule, with 25% of the shares vesting on the first anniversary of the vesting commencement date and the balance of the options vesting monthly in substantially equal installments over the following 36months, subject to the NEOs continued service through each vesting date.  Outstanding Equity Awards at 2025 Fiscal Year-End Table  The following table summarizes equity award","filed_date":"2026-03-16","accession":"0001104659-26-028062","full_text":"https://origin.rootz.global/static/filing/0001104659-26-028062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"mit a supplemental application to obexelimabs IgG4-RD BLA, if approved, and to include the bioequivalence data to a European MAA submission in the second half of 2026. In April 2026, we completed enrollment in the SunStone trial and expect to report topline results, including biomarker data, in the fourth quarter of 2026. Based on the outcome of the SunStone trial, and considering other factors, we m","filed_date":"2026-08-13","accession":"0001104659-26-095448","full_text":"https://origin.rootz.global/static/filing/0001104659-26-095448.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":16,"match_count":2,"context":"e not separated from the Common Stock and are not exercisable until the occurrence of a triggering event, except that such rights will be deemed to be distributed under this **clause (I**) upon their separation from the Common Stock or upon the occurrence of such triggering event) entitling them, for a period of not more than sixty (60) calendar days after the record date of such distribution, to subscribe for o","filed_date":"2026-03-31","accession":"0001104659-26-037821","full_text":"https://origin.rootz.global/static/filing/0001104659-26-037821.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"or delays in completing, or failing to complete, the development and commercialization of the Companys current product candidates or any fut ure product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effect s c aused by the Companys product candidates; potential competition, including fr","filed_date":"2025-06-04","accession":"0001104659-25-056215","full_text":"https://origin.rootz.global/static/filing/0001104659-25-056215.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"dule, with 25% of the shares vesting on the first anniversary of the  27 [TABLE OF CONTENTS](#TOC) vesting commencement date and the balance of the options vesting monthly in substantially equal installments over the following 36months, subject to the NEOs continued service through each vesting date.  The 2024 stock option grants made to our NEOs by our board of directors are shown in the following t","filed_date":"2025-04-28","accession":"0001104659-25-039765","full_text":"https://origin.rootz.global/static/filing/0001104659-25-039765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"s or delays in completing, or failing to complete, the development and commercialization of the Companys current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Companys product candidates; potential competition, including from","filed_date":"2026-03-16","accession":"0001104659-26-027961","full_text":"https://origin.rootz.global/static/filing/0001104659-26-027961.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"s or delays in completing, or failing to complete, the development and commercialization of the Companys current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Companys product candidates; potential competition, including from","filed_date":"2026-01-05","accession":"0001104659-26-000402","full_text":"https://origin.rootz.global/static/filing/0001104659-26-000402.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":8,"match_count":1,"context":"04,384) | | | (33,096) | | | Income tax benefit | | | 185 | | | | | | 185 | | | Net loss | | $ | (137,295) | | $ | (104,384) | | $ | (32,911) | | Revenue For the nine months ended September 30, 2025, revenue increased $10.0 million, compared to the same period in 2024. The increase is related to the one-time non-refundable upfront cash payment under the Zai License Agreement that was recognized upon delivery of the license and","filed_date":"2025-11-12","accession":"0001104659-25-109753","full_text":"https://origin.rootz.global/static/filing/0001104659-25-109753.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"s or delays in completing, or failing to complete, the development and commercialization of the Companys current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Companys product candidates; potential competition, including from","filed_date":"2025-10-27","accession":"0001104659-25-102317","full_text":"https://origin.rootz.global/static/filing/0001104659-25-102317.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":8,"match_count":1,"context":"provals and launches in other indications ZB021: a novel oral IL - 17AA/AF provides opportunity to expand pipeline within rheumatology and into other therapeutic areas including dermatology Eli Lilly acquisition of DICE Therapeutics for $2.4B for oral IL - 17 portfolio Eli Lilly partnership with Protagonist Therapeutics on oral IL - 23 program with up to $990M in total deal value Anti - IL - 17 Biologics: a blockbuster drug class for","filed_date":"2025-10-08","accession":"0001104659-25-097663","full_text":"https://origin.rootz.global/static/filing/0001104659-25-097663.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBIO","company":"Zenas BioPharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"s or delays in completing, or failing to complete, the development and commercialization of the Companys current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Companys product candidates; potential competition, including from","filed_date":"2025-09-02","accession":"0001104659-25-085982","full_text":"https://origin.rootz.global/static/filing/0001104659-25-085982.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"cb9d739baade617c8980ab55c48d7d5a545741151d65052dbc8f49cd76d92a74","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"9155258f45b5299f473cd6a0c5742a0e993c121acbc2b9ab64734b4adba8550b","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":1,"hourly_limit":500,"remaining":499,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}